Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H11I3NO2.Na |
| Molecular Weight | 592.9137 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC(CC1=C(I)C=C(I)C(N)=C1I)C([O-])=O
InChI
InChIKey=LEXZDSSHLHPSQC-UHFFFAOYSA-M
InChI=1S/C11H12I3NO2.Na/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14;/h4-5H,2-3,15H2,1H3,(H,16,17);/q;+1/p-1
| Molecular Formula | C11H11I3NO2 |
| Molecular Weight | 569.924 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
75 g single, oral Overdose |
unknown, 42 years |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (1 patient) Sources: |
3 g single, oral Recommended |
unknown, adult |
Other AEs: Gastrointestinal disorders... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Diarrhea | 1 patient Disc. AE |
75 g single, oral Overdose |
unknown, 42 years |
| Gastrointestinal disorders | 39 patients | 3 g single, oral Recommended |
unknown, adult |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. | 2013-06 |
|
| Identification of iopanoic acid as substrate of type 1 deiodinase by a novel nonradioactive iodide-release assay. | 2012-05 |
|
| Autoimmune thyroid diseases in children. | 2010-12-14 |
|
| Implication of type 3 deiodinase induction in zebrafish fin regeneration. | 2010-08-01 |
|
| Analysis by LC/ESI-MS of iophenoxic acid derivatives and evaluation as markers of oral baits to deliver pharmaceuticals to wildlife. | 2010-07-15 |
|
| Colloid formation by drugs in simulated intestinal fluid. | 2010-05-27 |
|
| Anesthetic considerations in a patient with amiodarone-induced thyrotoxicosis. | 2010 |
|
| A thyroid hormone deiodinase inhibitor can decrease cutaneous cell proliferation in vitro. | 2009-02 |
|
| Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. | 2009-02 |
|
| Effects and safety of iopanoic acid in cats administered levothyroxine. | 2009-02 |
|
| Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. | 2008-12 |
|
| Amiodarone-induced thyrotoxicosis. A review. | 2008-09 |
|
| Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis. | 2008-09 |
|
| Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. | 2008-08-29 |
|
| Vaccination of feral pigs (Sus scrofa) using iophenoxic acid as a simulated vaccine. | 2008-02-15 |
|
| [Rapid preoperative preparation with iopanoic acid in severe liver toxicity due to methimazole: anesthetic implications]. | 2008-02 |
|
| Morphological and biochemical changes in the Harderian gland of hypothyroid rats. | 2008-02 |
|
| Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. | 2008-01-31 |
|
| A fatal case of recurrent amiodarone-induced thyrotoxicosis after percutaneous tracheotomy: a case report. | 2007-11-13 |
|
| Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. | 2007-11 |
|
| An in vivo multiwell-based fluorescent screen for monitoring vertebrate thyroid hormone disruption. | 2007-08-15 |
|
| Hashimoto's thyroiditis and the role of selenium. Current concepts. | 2007-02-12 |
|
| Unliganded thyroid hormone receptor is essential for Xenopus laevis eye development. | 2006-10-18 |
|
| Long-lasting systemic bait markers for Eurasian badgers. | 2006-10 |
|
| Liquid chromatography-electrospray ionization mass spectrometry for direct identification and quantification of iophenoxic acid in serum. | 2006-02-17 |
|
| Comparison of enhancing effects of different goitrogen treatments in combination with beta-estradiol-3-benzoate for establishing a rat two-stage thyroid carcinogenesis model to detect modifying effects of estrogenic compounds. | 2006-01 |
|
| Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a randomized controlled trial. | 2005-12 |
|
| Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. | 2005-10 |
|
| Suppression of hypothalamic deiodinase type II activity blunts TRH mRNA decline during fasting. | 2005-08-29 |
|
| Percutaneous transcholecystic biliary interventions using gallbladder anchors: feasibility study in the swine. | 2005-07-08 |
|
| Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. | 2005-04 |
|
| Thyroid (dys)function in heart failure: is it a potential target for medical treatment? | 2005 |
|
| Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. | 2005 |
|
| Thyroid hormone-dependent seasonality in American tree sparrows (Spizella arborea): effects of GC-1, a thyroid receptor beta-selective agonist, and of iopanoic acid, a deiodinase inhibitor. | 2004-08 |
|
| Rapid preoperative preparation for severe hyperthyroid Graves' disease. | 2004-05 |
|
| Expression of type II iodothyronine deiodinase marks the time that a tissue responds to thyroid hormone-induced metamorphosis in Xenopus laevis. | 2004-02-01 |
|
| Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. | 2004-02 |
|
| Iopanoic acid in the management of neonatal Graves' disease. | 2004-02 |
|
| [Levothyroxine poisoning: clinical manifestations and therapeutic management]. | 2004-01 |
|
| Oral contrast-enhanced CT cholangiography--an initial experience. | 2004-01 |
|
| Rapid preparation of severe uncontrolled thyrotoxicosis due to Graves' disease with Iopanoic acid--a case report. | 2004-01 |
|
| Light-induced hormone conversion of T4 to T3 regulates photoperiodic response of gonads in birds. | 2003-11-13 |
|
| Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? | 2003-10 |
|
| Inhibition of drug binding to human serum albumin by cholecystographic agents. | 2003-09 |
|
| Thyroid hormones interact with glucocorticoids to affect somatotroph abundance in chicken embryonic pituitary cells in vitro. | 2003-09 |
|
| Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis. | 2003-08 |
|
| Perioperative management of the thyrotoxic patient. | 2003-06 |
|
| Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. | 2003-05 |
|
| Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis. | 2003-03 |
|
| Additive nephrotoxicity from roentgenographic contrast media. Its occurrence in phenazopyridine-induced acute renal failure. | 1981-05 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:00:16 GMT 2025
by
admin
on
Mon Mar 31 23:00:16 GMT 2025
|
| Record UNII |
439WET4G58
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
219-683-3
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | |||
|
m6371
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB02750MIG
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | |||
|
439WET4G58
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | |||
|
23669441
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | |||
|
340398
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID20947842
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | |||
|
100000086410
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY | |||
|
138711-85-0
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
SUPERSEDED | |||
|
2497-78-1
Created by
admin on Mon Mar 31 23:00:16 GMT 2025 , Edited by admin on Mon Mar 31 23:00:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
